Free CME from PeerView

Continuing Nursing Education (CNE) Activities

Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
StartThis activity expired on July 14, 2023; credit is no longer available.
Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
Activity Description and Educational Objectives
Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice.
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence
- Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy
- Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers
Target Audience
This activity has been designed to meet the educational needs of oncologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with advanced gastroesophageal cancer.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME/MOC credit and 75% or higher to obtain NCPD credit.
There are no prerequisites and there is no fee to participate in this
activity or to receive CME/MOC/NCPD credit. Statements of Credit are awarded
upon successful completion of the post-test and evaluation form.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: July 15, 2022 - July 14, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Yelena Y. Janjigian, MD
Associate Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Yelena Y. Janjigian, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Basilea Pharmaceutica
Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD
Serono, Inc.; Imugene Limited; Lilly; Merck & Co., Inc.; Michael J. Hennessy
Associates; Paradigm Medical Communications, LLC; Pfizer; Rgenix Inc.; Seagen
Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer Corporation; Bristol Myers Squibb;
Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Rgenix Inc; and U.S.
Department of Defense.
Stock Shareholder in Rgenix Inc.
Presenter
Steven Maron, MD, MSc
Assistant Attending
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Steven Maron, MD, MSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Basilea Pharmaceutica Ltd.; Bicara
Therapeutics; Daiichi Sankyo Inc.; Natera, Inc.; and Novartis Pharmaceuticals
Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6826-22-T.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer's product labeling.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity's topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView
This activity expired on July 14, 2023; credit is no longer available.
Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
Activity Description and Educational Objectives
Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice.
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence
- Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy
- Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers
Target Audience
This activity has been designed to meet the educational needs of oncologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with advanced gastroesophageal cancer.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME/MOC credit and 75% or higher to obtain NCPD credit.
There are no prerequisites and there is no fee to participate in this
activity or to receive CME/MOC/NCPD credit. Statements of Credit are awarded
upon successful completion of the post-test and evaluation form.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: July 15, 2022 - July 14, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Yelena Y. Janjigian, MD
Associate Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Yelena Y. Janjigian, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Basilea Pharmaceutica
Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD
Serono, Inc.; Imugene Limited; Lilly; Merck & Co., Inc.; Michael J. Hennessy
Associates; Paradigm Medical Communications, LLC; Pfizer; Rgenix Inc.; Seagen
Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer Corporation; Bristol Myers Squibb;
Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Rgenix Inc; and U.S.
Department of Defense.
Stock Shareholder in Rgenix Inc.
Presenter
Steven Maron, MD, MSc
Assistant Attending
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Steven Maron, MD, MSc, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Basilea Pharmaceutica Ltd.; Bicara
Therapeutics; Daiichi Sankyo Inc.; Natera, Inc.; and Novartis Pharmaceuticals
Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6826-22-T.
Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer's product labeling.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity's topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
StartThis activity expired on July 11, 2023; credit is no longer available.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes
Activity Description
The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
- Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
- Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Faculty Disclosures
Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical
Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene
Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in TG Therapeutics.
Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia
Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Pfizer.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 11, 2023; credit is no longer available.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes
Activity Description
The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
- Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
- Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Faculty Disclosures
Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical
Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene
Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in TG Therapeutics.
Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia
Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Pfizer.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
StartThis activity expired on June 29, 2023; credit is no longer available.
Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
Expert commentary is based on data presented at the European Hematology
Association and American Society of Clinical Oncology meetings 2022.*
*PeerView is an independent publisher of conference news and medical
education programs.
Media: Enduring Material
Activity Release Date: June 30, 2022
Activity Expiration Date: June 29, 2023
Time to Complete Activity: 30 minutes
Activity Description
Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, nurses, advanced practice nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with ALL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs
- Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations
- Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children’s Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals, Inc.
Speakers Bureau participant with Jazz Pharmaceuticals,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on June 29, 2023; credit is no longer available.
Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
Expert commentary is based on data presented at the European Hematology
Association and American Society of Clinical Oncology meetings 2022.*
*PeerView is an independent publisher of conference news and medical
education programs.
Media: Enduring Material
Activity Release Date: June 30, 2022
Activity Expiration Date: June 29, 2023
Time to Complete Activity: 30 minutes
Activity Description
Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, nurses, advanced practice nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with ALL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs
- Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations
- Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children’s Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals, Inc.
Speakers Bureau participant with Jazz Pharmaceuticals,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView


Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
StartThis activity expired on June 20, 2023; credit is no longer available.
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.
Target Audience
This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
- Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
- Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient/Planner
Benneth Chukwu
Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Taylor Chandler Walker, BC-TCT
Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView
This activity expired on June 20, 2023; credit is no longer available.
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.
Target Audience
This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
- Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
- Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient/Planner
Benneth Chukwu
Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Taylor Chandler Walker, BC-TCT
Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView

The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management
StartThis activity expired on June 20, 2023; credit is no longer available.
The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective
tissue disease that affects multiple organ systems. Pulmonary involvement,
particularly interstitial lung disease (ILD), occurs in the majority of
patients with SSc and is now the number one cause of death in SSc. Early
diagnosis is key and relies on evaluation of signs and symptoms, pulmonary
function tests, and high-resolution computed tomography. Until recently,
therapy for SSc-ILD has been limited to supportive care and
immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic
pulmonary fibrosis (IPF) have either received approval, or are in
development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and
has many comorbidities, interprofessional management is essential from
diagnosis throughout the disease course.
In this expert-led activity, you will be able to self-assess your baseline
levels of understanding, skill, and confidence, resulting in a tailored
educational experience focused on the areas where you need it most.
Target Audience
This activity has been designed to meet the educational needs of pulmonologists, rheumatologists, radiologists, pathologists, nurse practitioners, and other clinicians involved in the care of patients with systemic sclerosis-related interstitial lung disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing
- Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team
- Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lisa H. Lancaster, MD
Professor of Medicine
Director, Interstitial Lung Disease Program
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Lisa H. Lancaster, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Devpro Biopharma LLC; Pieris Pharmaceuticals, Inc.; and Pliant Therapeutics,
Inc.
Grant/Research Support from Biogen; Boehringer Ingelheim
Pharmaceuticals, Inc.; Celgene Corporation; F. Hoffmann-La Roche Ltd.;
FibroGen, Inc.; Galapagos NV; Galecto, Inc; Novartis Pharmaceuticals
Corporation; and Pliant Therapeutics, Inc.
Speakers Bureau participant with Boehringer Ingelheim
Pharmaceuticals, Inc.; Genentech, Inc.; and Veracyte, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled "The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management" has been registered to offer 0.5 Lifelong Learning credit in the American Board of Pathology's (ABPath) Continuing Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView
This activity expired on June 20, 2023; credit is no longer available.
The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective
tissue disease that affects multiple organ systems. Pulmonary involvement,
particularly interstitial lung disease (ILD), occurs in the majority of
patients with SSc and is now the number one cause of death in SSc. Early
diagnosis is key and relies on evaluation of signs and symptoms, pulmonary
function tests, and high-resolution computed tomography. Until recently,
therapy for SSc-ILD has been limited to supportive care and
immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic
pulmonary fibrosis (IPF) have either received approval, or are in
development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and
has many comorbidities, interprofessional management is essential from
diagnosis throughout the disease course.
In this expert-led activity, you will be able to self-assess your baseline
levels of understanding, skill, and confidence, resulting in a tailored
educational experience focused on the areas where you need it most.
Target Audience
This activity has been designed to meet the educational needs of pulmonologists, rheumatologists, radiologists, pathologists, nurse practitioners, and other clinicians involved in the care of patients with systemic sclerosis-related interstitial lung disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing
- Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team
- Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lisa H. Lancaster, MD
Professor of Medicine
Director, Interstitial Lung Disease Program
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Lisa H. Lancaster, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Devpro Biopharma LLC; Pieris Pharmaceuticals, Inc.; and Pliant Therapeutics,
Inc.
Grant/Research Support from Biogen; Boehringer Ingelheim
Pharmaceuticals, Inc.; Celgene Corporation; F. Hoffmann-La Roche Ltd.;
FibroGen, Inc.; Galapagos NV; Galecto, Inc; Novartis Pharmaceuticals
Corporation; and Pliant Therapeutics, Inc.
Speakers Bureau participant with Boehringer Ingelheim
Pharmaceuticals, Inc.; Genentech, Inc.; and Veracyte, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled "The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management" has been registered to offer 0.5 Lifelong Learning credit in the American Board of Pathology's (ABPath) Continuing Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
StartThis activity expired on June 16, 2023; credit is no longer available.
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Listen to our expert faculty as they discuss new and emerging therapies
for AA and AD, with a focus on mechanisms of action, efficacy and safety
profiles, nuances of administration and use, and risk:benefit profile. You
will also hear about novel therapies in late-stage development for the
treatment of moderate to severe AD and AA.
The Late Night inExchange format is designed to meet the educational needs of
clinicians with practice-relevant education presented in an engaging
multi-faculty discussion format that brings knowledge to life. Through this
format, learners will be better able to see how conceptual knowledge of AA
and AD translates to actual practice.
Target Audience
This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
- Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
- Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
- Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics;
Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries
Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis
U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California
Lawrence Eichenfield, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis
Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd;
Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma
Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.;
Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics;
Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and
Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences,
Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of
Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.
Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community
(PRIME-LC)
Santa Ana, California
Charles Vega, MD, FAAFP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson
Services, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Pfizer.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on June 16, 2023; credit is no longer available.
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Listen to our expert faculty as they discuss new and emerging therapies
for AA and AD, with a focus on mechanisms of action, efficacy and safety
profiles, nuances of administration and use, and risk:benefit profile. You
will also hear about novel therapies in late-stage development for the
treatment of moderate to severe AD and AA.
The Late Night inExchange format is designed to meet the educational needs of
clinicians with practice-relevant education presented in an engaging
multi-faculty discussion format that brings knowledge to life. Through this
format, learners will be better able to see how conceptual knowledge of AA
and AD translates to actual practice.
Target Audience
This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
- Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
- Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
- Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics;
Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries
Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis
U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California
Lawrence Eichenfield, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis
Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd;
Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma
Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.;
Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics;
Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and
Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences,
Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of
Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.
Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community
(PRIME-LC)
Santa Ana, California
Charles Vega, MD, FAAFP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson
Services, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Pfizer.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
StartThis activity expired on July 4, 2023; credit is no longer available.
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Media: Enduring Material
Activity Release Date: June 5, 2022
Activity Expiration Date: July 4, 2023
Time to Complete Activity: 90 minutes
Activity Description
Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel
therapeutic strategy in leukemic and lymphoid malignancies, continues to
provide new hope for many patients, including those with multiple myeloma,
with limited treatment options. Multiple new indications for CAR T-cell
therapies have been approved by the FDA already this year, and new research
may expand treatment options for patients with heavily pretreated disease or
those receiving earlier lines of treatment. With these new therapeutic
opportunities, questions arise regarding best practices for using CAR T-cell
therapy in the clinic.
Check out PeerView’s “Seminars and Tumor Board” program featuring the latest
research and expert guidance on the role of CAR T-cell therapy in modern
hematologic cancer care. Gain a thorough understanding of the latest efficacy
and safety data on these therapies, and learn how to manage the practical
aspects of implementing these therapies in the care of patients with
hematologic malignancies. With patient cases drawn from practice, our faculty
will guide participants through important clinical considerations, including
referral of patients to specialized centers, coordination of care, and
detecting and managing distinctive CAR T-cell therapy–related adverse events
such as cytokine release syndrome (CRS) and immune effector cell
neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more
about the timely, safe, and efficacious use of CAR T-cell therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, advanced practice clinicians (including oncology NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with hematologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies
- Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support
- Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jason Westin, MD, MS, FACP
Associate Professor
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jason Westin, MD, MS, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for ADC Therapeutics SA; AstraZeneca;
Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; Merck &
Co., Inc.; Monte Rosa Therapeutics, Inc.; MorphoSys AG; Novartis
Pharmaceuticals Corporation; and Umoja Biopharma.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; MorphoSys
AG; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Shannon L. Maude, MD, PhD
Cancer Immunotherapy Program
The Children’s Hospital of Philadelphia
Assistant Professor of Pediatrics
Medical Director, Center for Cellular Immunotherapies
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Shannon L. Maude, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Grant/Research Support from Novartis Pharmaceuticals Corporation and
Wugen.
Faculty/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene
Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend
Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers
Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.;
Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Bristol Myers Squibb, Kite, A Gilead Company, Legend Biotech, and Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of
this CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.5 MOC points and patient safety MOC
credit in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider's responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 4, 2023; credit is no longer available.
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Media: Enduring Material
Activity Release Date: June 5, 2022
Activity Expiration Date: July 4, 2023
Time to Complete Activity: 90 minutes
Activity Description
Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel
therapeutic strategy in leukemic and lymphoid malignancies, continues to
provide new hope for many patients, including those with multiple myeloma,
with limited treatment options. Multiple new indications for CAR T-cell
therapies have been approved by the FDA already this year, and new research
may expand treatment options for patients with heavily pretreated disease or
those receiving earlier lines of treatment. With these new therapeutic
opportunities, questions arise regarding best practices for using CAR T-cell
therapy in the clinic.
Check out PeerView’s “Seminars and Tumor Board” program featuring the latest
research and expert guidance on the role of CAR T-cell therapy in modern
hematologic cancer care. Gain a thorough understanding of the latest efficacy
and safety data on these therapies, and learn how to manage the practical
aspects of implementing these therapies in the care of patients with
hematologic malignancies. With patient cases drawn from practice, our faculty
will guide participants through important clinical considerations, including
referral of patients to specialized centers, coordination of care, and
detecting and managing distinctive CAR T-cell therapy–related adverse events
such as cytokine release syndrome (CRS) and immune effector cell
neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more
about the timely, safe, and efficacious use of CAR T-cell therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, advanced practice clinicians (including oncology NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with hematologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies
- Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support
- Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jason Westin, MD, MS, FACP
Associate Professor
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jason Westin, MD, MS, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for ADC Therapeutics SA; AstraZeneca;
Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; Merck &
Co., Inc.; Monte Rosa Therapeutics, Inc.; MorphoSys AG; Novartis
Pharmaceuticals Corporation; and Umoja Biopharma.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; MorphoSys
AG; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Shannon L. Maude, MD, PhD
Cancer Immunotherapy Program
The Children’s Hospital of Philadelphia
Assistant Professor of Pediatrics
Medical Director, Center for Cellular Immunotherapies
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Shannon L. Maude, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Grant/Research Support from Novartis Pharmaceuticals Corporation and
Wugen.
Faculty/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene
Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend
Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers
Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.;
Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Bristol Myers Squibb, Kite, A Gilead Company, Legend Biotech, and Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of
this CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.5 MOC points and patient safety MOC
credit in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider's responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
StartThis activity expired on July 3, 2023; credit is no longer available.
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
Media: Enduring MaterialActivity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes
Activity Description
Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.Educational Objectives
Upon completion of this activity, participants should be better able to:- Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
- Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
- Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner Disclosures
Chair/PlannerHussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France
Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.
Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida
Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.Accreditation, Support, and Credit


Support
This activity is supported through an educational grant from Bristol Myers Squibb.Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.MOC Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.Copyright © 2000-2022, PeerView
This activity expired on July 3, 2023; credit is no longer available.
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
Media: Enduring MaterialActivity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes
Activity Description
Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.Educational Objectives
Upon completion of this activity, participants should be better able to:- Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
- Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
- Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner Disclosures
Chair/PlannerHussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France
Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.
Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida
Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.Accreditation, Support, and Credit


Support
This activity is supported through an educational grant from Bristol Myers Squibb.Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.MOC Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.Copyright © 2000-2022, PeerView

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
StartThis activity expired on July 2, 2023; credit is no longer available.
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes
Activity Description
For individuals with multiple sclerosis (MS), “invisible symptoms” that
include cognitive changes and fatigue exacerbate the burden of disease.
Emerging evidence indicates that in addition to providing high efficacy,
safety, tolerability, and patient convenience, sphingosine 1-phosphate
receptor (S1PR) modulators may yield important benefits related to loss of
cortical gray matter and whole brain volume, addressing cognition as well as
multiple other aspects of MS.
At a recent live event, our expert faculty reviewed the mechanism of action
of S1PR modulators and their important role in MS care, with a focus on the
clinically relevant distinctions among members of this class—from
first-generation fingolimod to the more recently introduced siponimod,
ozanimod, and ponesimod. The faculty discussed the role of agent-specific
characteristics such as relative selectivity and off-target effects in
individualized treatment planning—reviewing key trial data on patient
outcomes and concluding with a case-based workshop addressing treatment
selection, shared decision-making, and COVID-19 vaccination.
Target Audience
This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
- Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
- Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California
Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara
Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD
Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals
Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio,
Inc.
Grant/Research Support from Genentech, Inc.
Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia
Heidi Crayton, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen;
EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.
LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD
Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and
sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.;
Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation;
sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 2, 2023; credit is no longer available.
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes
Activity Description
For individuals with multiple sclerosis (MS), “invisible symptoms” that
include cognitive changes and fatigue exacerbate the burden of disease.
Emerging evidence indicates that in addition to providing high efficacy,
safety, tolerability, and patient convenience, sphingosine 1-phosphate
receptor (S1PR) modulators may yield important benefits related to loss of
cortical gray matter and whole brain volume, addressing cognition as well as
multiple other aspects of MS.
At a recent live event, our expert faculty reviewed the mechanism of action
of S1PR modulators and their important role in MS care, with a focus on the
clinically relevant distinctions among members of this class—from
first-generation fingolimod to the more recently introduced siponimod,
ozanimod, and ponesimod. The faculty discussed the role of agent-specific
characteristics such as relative selectivity and off-target effects in
individualized treatment planning—reviewing key trial data on patient
outcomes and concluding with a case-based workshop addressing treatment
selection, shared decision-making, and COVID-19 vaccination.
Target Audience
This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
- Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
- Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California
Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara
Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD
Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals
Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio,
Inc.
Grant/Research Support from Genentech, Inc.
Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia
Heidi Crayton, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen;
EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.
LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD
Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and
sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.;
Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation;
sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
StartThis activity expired on July 1, 2023; credit is no longer available.
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to
identify additional novel interventions to address multiple sclerosis (MS)
pathophysiology and help to individualize care. Four BTK
inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in
phase 3 clinical trials for relapsing and/or progressive MS, based on the
potential of these agents to affect processes mediated by B cells and myeloid
cells (eg, microglia), which may contribute to inflammation and
neurodegeneration.
At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted
the rationale for using BTK inhibitors to treat MS, assessed the latest data
from completed and ongoing clinical trials, and reviewed
guideline-recommended protocols for patient imaging. In addition to the
lively discussion, animated video abstracts further illustrated these
topics.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
- Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
- Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
- Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas
Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD
Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon
Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals
Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and
Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive
role/ownership interest.
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi
Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 1, 2023; credit is no longer available.
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to
identify additional novel interventions to address multiple sclerosis (MS)
pathophysiology and help to individualize care. Four BTK
inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in
phase 3 clinical trials for relapsing and/or progressive MS, based on the
potential of these agents to affect processes mediated by B cells and myeloid
cells (eg, microglia), which may contribute to inflammation and
neurodegeneration.
At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted
the rationale for using BTK inhibitors to treat MS, assessed the latest data
from completed and ongoing clinical trials, and reviewed
guideline-recommended protocols for patient imaging. In addition to the
lively discussion, animated video abstracts further illustrated these
topics.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
- Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
- Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
- Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas
Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD
Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon
Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals
Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and
Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive
role/ownership interest.
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi
Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView








